Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Chewy Inc (CHWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Chewy Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.03 (market cap $39.89B), while Chewy Inc trades at $20.26 (market cap $8.55B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.7× Chewy Inc's market cap. Which is the better fit depends on your goals.
| ALNY | CHWY | |
|---|---|---|
Market Cap | $39.89B | $8.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $42.33 |
52-Week Low | $278.09 | $17.51 |
Enterprise Value | $38.15B | $8.51B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Chewy (CHWY) trades at $20.88, up 1.02% today, but remains under pressure with a bearish technical signal and recent earnings misses. The company reported strong revenue growth to $11.86B in 2025 and improved net income of $393M, yet faces margin compression and lowered FY26 sales guidance. Analyst sentiment remains overwhelmingly positive with 81.58% buy ratings and a $34.92 consensus target, suggesting significant upside potential from current levels despite near-term challenges.
The investment case balances attractive valuation metrics (P/S 0.69) against cyclical headwinds and competitive pressures. While operational cash flow growth and market share gains in pet healthcare provide long-term catalysts, investor caution is warranted given recent guidance reductions and volatile technical positioning near key support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Chewy Inc
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →
